Agreements (Details 4) (Biotest, Exclusive development and commercialization license, USD $)	1 Months Ended		1 Months Ended
Jul. 31, 2006	Jul. 31, 2006 Maximum	Sep. 30, 2008 Phase I clinical trial	Jul. 31, 2006 Development milestones	Jun. 30, 2013 Development milestones Phase IIb clinical trial	Jul. 31, 2006 Regulatory milestones
Collaborative Agreements disclosures
Payments received under collaboration agreement	$ 1,000,000		$ 500,000
Potential milestone payments receivable		35,500,000		4,500,000	2,000,000	31,000,000
Opt-in-fee payable on exercise of right	$ 15,000,000

Cash received from collaborators during the current period.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 27

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

Name:	us-gaap_ProceedsFromCollaborators
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration